Evidence map›Paper›PMID 42841061›Full record

ArticleNeuro-oncology advances

Clinical factors associated with leptomeningeal disease in patients with melanoma brain metastasis.

Merve Hasanov, Christina A Faraj, Denai R Milton, Subhiksha Srinivasan, Eric A Goethe, Ian E McCutcheon, Jeffrey S Weinberg, Isabella C Glitza Oliva, Sherise D Ferguson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Merve HasanovDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).
Christina A FarajDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).ORCID https://orcid.org/0000-0002-6441-4291
Denai R MiltonDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).
Subhiksha SrinivasanDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).
Eric A GoetheDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).
Ian E McCutcheonDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).
Jeffrey S WeinbergDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).
Isabella C Glitza OlivaDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).ORCID https://orcid.org/0000-0002-4530-7765
Sherise D FergusonDepartment of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio (M.H.); Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas (C.A.F., S.S., E.A.G., I.E.M., J.S.W., S.D.F.); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (D.R.M.); Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (I.C.G.O.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Leptomeningeal disease (LMD) is a severe manifestation of metastatic cancer with limited treatment options and a poor prognosis. Melanoma has one of the highest rates of leptomeningeal spread among solid tumors. Given the associated morbidity and mortality, identifying clinical factors linked to LMD in patients with melanoma brain metastases (MBM) is crucial. Methods: We conducted a retrospective study of 829 MBM patients diagnosed at MD Anderson Cancer Center (2009-2018). The primary outcome measure was time from MBM to LMD. Cumulative incidence of LMD was determined using the competing risks method, where death was the competing risk. Differences in cumulative incidences were assessed using Gray's test, and associations between measures of interest and cumulative incidence were determined using proportional sub-distribution hazards models. Results: Among 829 patients, 129 (16%) developed LMD (median follow-up: 12.1 months, range: 0.0-156.2 months). Median time from MBM diagnosis to LMD was 5.5 months. Of those with known mutation status ( Conclusion: LMD is a dire consequence of advanced melanoma, yet the clinical features associated with its development are not fully characterized. Identifying clinical predictors may guide management of high-risk populations.

Indexed as

brain metastasiscraniotomyleptomeningeal diseasemelanoma

Identifiers

PMID42841061
PMCPMC13641070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.